ArticleFrontiers in neurology2026
A web-based radiomics nomogram combining MRI features and clinical data for predicting 30-day progression of acute ischemic stroke: a two-center study.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate an integrated nomogram combining MRI radiomics features with clinical variables for predicting 30-day progression risk in patients with acute ischemic stroke (AIS), and to deploy a web-based visualization tool for clinical application. Methods: This retrospective two-center study included 254 AIS patients. Radiomics features were extracted from DWI using MaZda, and key features were selected by LASSO logistic regression to build a radiomics signature. Clinical predictors were identified using logistic regression. Radiomics, clinical, and combined models were developed and evaluated using area under the curve (AUC), net reclassification index (NRI), and integrated discrimination improvement (IDI), calibration analysis, and decision curve analysis (DCA). Optimal cutoffs were determined in the training cohort using the Youden index and then directly applied to the external validation cohort without re-optimization. The corresponding training-derived thresholds were -1.2023 for the clinical model, -1.0368 for the radiomics model, and -2.3639 for the combined model. Bootstrap resampling (1,000 repetitions) was used for internal validation of the combined model. Results: Eight optimal radiomics features were selected from 300 extracted features. Multivariate analysis identified four independent predictors: Radiomics score (Radscore) (OR = 2.23, 95% CI: 1.28-5.11), National Institutes of Health Stroke Scale (NIHSS) score (OR = 1.57, 95% CI: 1.25-2.14), type 2 diabetes mellitus (OR = 9.28, 95% CI: 2.02-56.03), and monocytes (MO) (OR = 1.08, 95% CI: 1.02-1.16). The combined model showed favorable discriminative performance with AUCs of 0.945 (95%CI: 0.903-0.987) and 0.904 (95% Conclusion: The integrated radiomics-clinical nomogram incorporating Radscore, NIHSS score, type 2 diabetes mellitus (T2DM), and MO showed potential for predicting 30-day progression risk in patients with AIS. This web-based tool may support early risk stratification, but further large-scale prospective validation is required before routine clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.